Abstract Endothehal function 1s known to be ImpaIred m essential hypertensive patients In this study, we examined whether antihypertensive drugs improve forearm vasochlatory response to reactive hyperenna m 26 patients with essential hypertension (6222 years) without dtabetes melhtus, hyperhpldemla, coronary heart disease, or cerebrovascular disease AntIhypertensive drugs were never given or were chscontmued for at least 4 weeks before the study Patients were treated with monotherapy of &her temocaprtl (2 or 4 mg, n= 15) or amlochpme (2 5 or 5 mg, n= 11) for 6 months Forearm blood flow was measured by strain-gauge plethysmography Vasodilator response to the release of upper arm compression at 300 mm Hg for 5 minutes and to sublingual admmistration of mtroglycenn (0 3 mg) were assessed Changes of forearm blood flow response to reactive hyperenna were sigmficantly less m hypertensive patients (99218%) than m age- E ndothehal cells play a pIvota role m the modulation of vascular tone by releasing vasoactive substances, such as endothelm, prostaglandm, and endothelium-derived relaxing factor (EDRF). 1~2 In the early stage of atherogenesis, endothehal cell function 1s known to be disturbed.3 This results in lmpairment of the vasochlator response to acetylcholme, which requires Intact endothehal function 4 There 1s considerable evidence that the endothehum-dependent vasodilation 1s impaired in human essential hypertenslon.5.10 The effects of various antlhypertenslve drugs on hypertension-induced endothehal dysfunction have been examined widely. In animal studies, angiotensmconverting enzyme (ACE) mhWors have been shown to improve endothehal function. II-14 However, m human hypertension, the results are not consistent, several investigators demonstrated that ACE mhibltors improved endothelial dysfunction m hypertensive patients,l5-17 while others failed to show an lmprovement 18,19 The effect of calcium antagonists has not been fully examined except m rats13 and an acute human study '6 CelermaJer et al*0 evaluated endothehal function by Doppler system m the brachlal and femoral arteries during reactive hyperemla and after sublmgual adnumstration of nitroglycerm. Both procedures induce vasochlation; however, the former 1s partly mediated by
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Correspondence to Masahm, Nagano, MD, Head of the Department of Cardiology Hlgashlosaka Mumclpal Central Hospital 2-3-l Mikunyammanu, Hlgashlosaka 577 Japan E-mail nagano@ gerlat med Osaka-u ac JP 0 1997 American Heart Assoclatlon, Inc EDRF,2',22 while the latter acts directly on smooth muscle cells. In this study, we used CelermaJor's method with modlficatlon to evaluate the effects of an ACE mhlbitor, temocapnl, and a calcium antagonist, amlochpine, on forearm vasodllator response m patients with essential hypertension These drugs were given as monotherapy for 6 months in hypertensive patients without any overt chnlcal evidence of atherosclerosis
Subjects

Methods
The SubJects were 26 panents with essential hypertension aged 52 to 80 years (mean+-SEM, 62?2 years) and another 37 age-and sexmatched normotensive mdividuals as control Hypertension was defined as systolic blood pressure at the outpatient department of 160 mm Hg or higher and/or diastolic blood pressure of 95 mm Hg or higher m the sittmg positron on at least three separate visits Secondary hypertension was excluded by routme physical and laboratory exammations SubJects with diabetes melhtus, dyshppldernia, arrhythrma, or cerebrovascular disease were excluded by chmcal and laboratory exammatlons SubJects suspected to have coronary artery disease from theu chmcal symptoms or electrocarchogram underwent coronary angiography and those with coronary artery disease were excluded from the study Hypertensive patients were admmlstered ather temocapnl (n=15, Sankyo Co Ltd) or amlodlpme (n= 11, Surmtomo Pharmaceuticals) once diuly for 6 months huhal dose was 2 mg for temocaprd or 2 5 mg for amlochpme When the blood pressure was not decreased by 20/10 mm Hg or to below 150/ 90 mm Hg, the dose of either drug was doubled When blood pressure control was not achieved with monotherapy of either drug, the SubJect was excluded from the study All patients had either never been treated (n= 13) or had dlscontmued a&hypertensive drugs such as P-blocker (n=3), converting enzyme mhWor (n=5), or calcmm antagomst (n=5) for at least 4 weeks before the study
Measurement of Forearm Blood Flow
The study was conducted m a temperature-controlled dark quiet room SubJects rested for 15 minutes m the supme posltlon before the study. Forearm blood flow was measured by stramgauge plethysmography (model ECSR, DE Hokanson, Inc) 23 A mercury-m-Silastic stram gauge that had been electrlcally cahbrated was placed on the widest part of the forearm The pressure of the collectmg cuff was set at 40 mm Hg and occlusion pressure of the wrist cuff was 200 mm Hg or 20 mm Hg more than systolic blood pressure After obtaining the baselme value of forearm blood flow, the upper arm was compressed by inflation of a pneumatic tourmquet at a pressure of 300 mm Hg for 5 minutes At 60 and 90 seconds after cuff deflation, the second measurement was performed. At least 15 minutes after the last measurement, blood flow was measured to confirm that the blood flow had returned to the basal level Then, mtroglycerm was sublmgually admmlstered at 300 pg by one puff of a spray device (Mlokol Spray, Toa Elyo) Then the measurement was repeated at 3, 4, and 5 minutes after the admmistratlon This response was used as control Forearm blood flow was recorded for 5 seconds and expressed as mllhhters of blood per minute per 100 mL of forearm volume Maximum changes m blood flow after both mterventions were expressed as the percent change of the pretreatment values The overall recordmgs were analyzed by the same mvestigator blinded to the subjects' background Blochemlcal factors were measured m blood collected m the morning after overnight fasting The study protocol was approved by the Ethical Committee Informed consent was obtained from each subject before the study
Statistical Analysis
Data are expressed as mean+SEM Differences between two groups were assessed by the unpaired t test with two tads, and those among groups were assessed by analysis of variance followed by Bonferrom's test. Differences of changes m blood pressure and vasochlator responses by the treatment with antlhypertensive drugs were assessed by analysis of variance with repeated measurements. A value of P<.O5 was regarded as slgmficant Results Table 1 shows the background of study subjects Compared with normotensive SubJects, blood pressure and left ventricular mass index were higher m hypertensive groups, while these parameters were slml1a.r m the two hypertensive groups Other factors were not different among the three groups (Table 1) (Fig 1) However, forearm response to reactive hyperemla m hypertensive patients was ugmficantly less than that m normotenslve subjects (Fig 1) . Blood pressure was well controlled by 2 mg (n= 10) or 4 mg (n=5) temocaprd, or 25 mg (n=5) or 5 mg (n=6) amlodipme. Treatment with monotherapy of either temocaprll or amlodlpme for 6 months produced a similar reduction of blood pressure and left ventricular mass index, while heart rate was not changed by either drug (Table 2) Vasodllator response to reactive hyperemla and mtroglycerm before treatment was similar between the two groups Nltroglycerm-induced vasoddatlon was not altered by treatment with either drug (Fig 2) Forearm vascular response to reactive hyperemla was not changed by amlodlpme but was significantly improved by temocaprd 0% 3)
Discussion
Our results show that forearm vasoddator response to reactive hyperemra IS impaired m patients with essential hypertension without any overt atherosclerotic disease or in our normotensive SubJects (4.92~0 2 mmol/L) than in another study (6.0+_0.1 mmol/L).*6 Therefore, the lack of difference m endothelial function between normotensive and hypertensive SubJects m their study may have been due to mild hyperhprdemia m the normotensrve subjects, which might have impaired endothehal function Our data indicated that the ACE inhibitor temocapril rmproves forearm vascular response to reactive hyperemra, while amlodipine does not alter it. Treatment with amlodrpme and temocapnl produced similar blood pressure reduction at 6 months after the treatment Both drugs are long-lasting antrhypertensrve drugs that are usually given once a day. Therefore, rt is unlikely that the difference m the duration of normotensron may explam the results obtamed m this study
The mechanism by which ACE inhibitor improves flowmediated vasodtlatron 1s thought to be multrfactonal. First, ACE mhlbrtors induce accumulation of bradykmin by mhrbrtron of kminase II Bradykmm causes the release of EDRF from endothehal cells. Treatment wrth ACE mhrbnor may therefore increase the release of EDRF from endothelium 28~~~ Second, ACE mhtbrtors are known to suppress the renm-angrotensm system not only m the errculatlon but also m the cardiovascular system, eg, the heart30 and vascular tissue.31 Angiotensm II is not only one of the most potent vasoconstnctors known but also strmulates the release of other vasoconstrtcting factors such as endothelm32 and prostaglandm HZ33 from endothehal cells These data suggest that ACE mhrbrtors may improve vasomotor functron by reducing levels of these vasoconstrictmg substances Finally, angiotensm II 1s reported to increase the achvity of vascular NADH oxrdase m vitro34 and m vivo 35 This oxrdase 1s a source of vascular superoxide which inactivates mtnc oxide. Therefore, ACE mhibrtors may reduce angrotensm II level and superoxrde activity, resulting m the restoratron of nitric oxrde-medrated vasodtlatron. Our results mdrcate that treatment with amlodrpme has no effect on forearm response to reactive hyperemra m hypertensive patients It is possible that the durahon of amlodlpme treatment was not sufficient to cause beneficial effects on endothehal cells. However, it has been reported that EDRF release from endothehal cells 1s calcmm dependent.36.37 In m vitro studies, calcium channel agonist caused endothelmm-dependent vasodrlation,38 while calcium antagonist diminished EDRF release,39 suggesting that treatment with a calcium antagonist attenuates endothelium-dependent vasodilation. Another study showed that verapamrl, diltrazem, and mfedrpme had no effect on basal and bradykmm-stimulated release of nitrrc oxide from aortic endothehal cells m culture 4O Although direct effects of amlodrpme on endothehal cells were not shown, these studies and our data suggest that calcmm antagonists do not affect endothehal function Although the averaged value of vasodrlator response was not changed by amlodrpme, actual value m 6 patients showed the increase m forearm response to reactive hyperemra Therefore, rt 1s possible that the longer treatment of amlodlpme improves vasodtlator response
The mechanism of postlschemrc hyperemra 1s thought to be multtfactonal. In the human forearm, reactive hyperemta after 3 to 5 minutes' occlusion was decreased by mhrbrtron of prostaglandm synthesis with ibuprofen or A goal of hypertension treatment is not only to lower the blood pressure but to treat hypertension-induced target organ disease ACE mhibitors are known to be useful for the treatment of left ventricular hypertrophy,4" congestive heart failure,4 and chronic renal insufficiency 45 In the TREND (Trial on Reversing Endothelial Dysfunction) study,46 the effect of an ACE inhibitor qumapril on endothehal function was assessed using double-blinded, randomized, placebo-controlled design In normotensive patients with coronary artery disease, response of coronary arteries to acethylcholme was evaluated by quantitative coronary angiography. Stx months' treatment with qumapril improved the response to acethylcholme, suggesting the improvement of endothehal function by qumapril These and our results suggest that ACE mhibttors are useful for treating essential hypertensive patients having cardiovascular complications. We did not measure the blood flow until 60 seconds after the release of arm compresston. Therefore, it is possible that the peak response occurs within 60 seconds, which might be affected by the antihypertensive drugs. Our results suggest that temocapril attenuates the poor vasodtlator response to reactive hyperemia Similar results were obtained by using other ACE mhtbitors,l5-r7 though further study 1s required to know whether this effect is pecuhar to a specific type of ACE mhtbitor We examined the effect of two antihypertensive drugs m the different groups of patients The crossover design may be more appropriate to evaluate the effects of the different classes of drugs nitric oxide dilator mechamsm appears abnormal J 
